StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
065660.KQ$25250.00-5.43%
Fair $25250.00+0.0%

065660.KQ

Anterogen.Co.,Ltd.

Unknown / UnknownKOSDAQ

$25250.00

-1450.00 (-5.43%)

Fairly Valued+0.0%Fair Value $25250.00Fund rank 26/100 · Data gapFallback financials|
SA 6/F
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 20%

FCF escenarios

weak_data · normalized FCF $-1.3B · quality 53.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 33/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

6/100

F

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -1.6%, below the 5% threshold
Thesis & Journal · 065660.KQLocal privado en este navegador · Anterogen.Co.,Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$252.7B

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-1.6%

↓

Gross Margin

35.3%

↑

Debt/Equity

N/A

•
52-Week Range$25250
$19380$61800

TradingView lightweight chart

065660.KQ price, volumen y niveles de valoración

Último $25,250Periodo -35.4%
Fair value: $25,250

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+4.6%

FCF CAGR

—

FCF margin

-17.1%

FCF / Net income

0.94x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $7.54B · net income $-1.37B · FCF $-1.29B

2022-FY → 2025-FY

Gross margin

35.3%-4.3% pts

Operating margin

-32.3%+38.2% pts

Net margin

-18.2%+85.5% pts

FCF margin

-17.1%+35.4% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$7.54B$7.54B$6.93B$6.50B$6.59B
Net Income$-1.37B$-1.37B$-2.29B$-2.84B$-6.84B
EBITDA$-1.84B$-1.84B$-1.45B$-484.4M$-4.39B
EPS-138.00-138.00-236.00-292.00-706.00
Gross Margin35.3%35.3%37.9%41.0%39.7%
Operating Margin-32.3%-32.3%-54.1%-78.1%-70.5%
Net Margin-18.2%-18.2%-33.1%-43.7%-103.7%
Balance Sheet
Debt/Equity———0.080.12
Cash Flow
Free Cash Flow$-1.29B$-1.29B$-1.17B$-2.19B$-3.46B
Returns
ROE-1.6%-1.6%-2.1%-2.2%-6.4%
Valuation
P/B2.872.871.691.141.34
Growth & Yield
Revenue Growth8.7%8.7%6.7%-1.4%—
EPS Growth41.5%41.5%19.2%58.6%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +11.5%

Total return

+11.5%

Start / end P/E

n/dx → n/dx

EPS bridge

-236.00 → -138.00

Residual

+11.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+11.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.